McGuire, Darren K.

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 168

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial

Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 167

Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA

McGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 164

Impaired glucose tolerance and impaired fasting glucose — a review of diagnosis, clinical implications and management

Petersen, J. L., & McGuire, D. K. (2005) · Diabetes and Vascular Disease Research

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 159

Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus

Berg, D. D., Wiviott, S. D., Scirica, B. M., Gurmu, Y., Mosenzon, O., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 154

Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project

Arnold, S. V., Inzucchi, S. E., Tang, F., McGuire, D. K., Mehta, S. N., Maddox, T. M., Goyal, A., Sperling, L. S., Einhorn, D., Wong, N. D., et al. (2017) · European Journal of Preventive Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 144

Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes

Pandey, A., Vaduganathan, M., Patel, K. V., Ayers, C., Ballantyne, C. M., Kosiborod, M. N., Carnethon, M., DeFilippi, C., McGuire, D. K., Khan, S. S., et al. (2021) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 144

Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization

Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 139

Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL , a randomized trial

McGuire, D. K., Busui, R. P., Deanfield, J., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N., Engelmann, M. D. M., Hovingh, G. K., et al. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 131

Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review

Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 127

Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

Pandey, A., Patel, K. V., Bahnson, J. L., Gaussoin, S. A., Martin, C. K., Balasubramanyam, A., Johnson, K. C., McGuire, D. K., Bertoni, A. G., Kitzman, D., et al. (2020) · Circulation

Cardiovascular Function and Risk FactorsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 127

SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation

Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 123

The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58

Mosenzon, O., Wiviott, S. D., Heerspink, H. J. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., Rozenberg, A., Schechter, M., Yanuv, I., Murphy, S. A., et al. (2021) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 113

Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Kelsey, M. D., Nelson, A. J., Green, J. B., Granger, C. B., Peterson, E. D., McGuire, D. K., & Pagidipati, N. J. (2022) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 106

Metabolic Effects of Exercise Training Among Fitness-Nonresponsive Patients With Type 2 Diabetes: The HART-D Study

Pandey, A., Swift, D. L., McGuire, D. K., Ayers, C. R., Neeland, I. J., Blair, S. N., Johannsen, N., Earnest, C. P., Berry, J. D., & Church, T. S. (2015) · Diabetes Care

Cardiovascular and exercise physiologyPhysical Activity and Health

Cited by 83

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Nelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 78

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial

Nissen, S. E., Lincoff, A. M., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Ridker, P. M., Ray, K. K., McGuire, D. K., Mozaffarian, D., Koenig, W., et al. (2021) · JAMA Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 76

Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity

Sattar, N., Presslie, C., Rutter, M. K., & McGuire, D. K. (2024) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 70

Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial

Marx, N., Deanfield, J. E., Mann, J. F. E., Arechavaleta, R., Bain, S. C., Bajaj, H. S., Bayer Tanggaard, K., Birkenfeld, A. L., Buse, J. B., Davicevic-Elez, Z., et al. (2025) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 70

Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial

Segar, M. W., Patel, K. V., Vaduganathan, M., Caughey, M. C., Butler, J., Fonarow, G. C., Grodin, J. L., McGuire, D. K., & Pandey, A. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 70

Metformin in Heart Failure

Inzucchi, S. E., Masoudi, F. A., & McGuire, D. K. (2007) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 64

Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials

Lee, M. M. Y., Sattar, N., Pop-Busui, R., Deanfield, J., Emerson, S. S., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N. R., et al. (2025) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 63

Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial

Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 62

Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes.

Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 56